{
    "clinical_study": {
        "@rank": "23400", 
        "acronym": "IEMO", 
        "arm_group": [
            {
                "arm_group_label": "Intranasal Oxytocin", 
                "arm_group_type": "Experimental", 
                "description": "Participants will be randomized to receive 72 IU intranasal oxytocin on either study visit 2 or 3"
            }, 
            {
                "arm_group_label": "Saline Nasal Mist", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Participants will be randomized to receive intranasal saline mist (placebo) on opposite visits from the interventional drug visit 2 or 3"
            }
        ], 
        "brief_summary": {
            "textblock": "This study will evaluate the effects on emotions and neural activity of a one time dose of\n      intranasal oxytocin vs. placebo in patients with FTD and healthy controls."
        }, 
        "brief_title": "Impact of Emotional Mimicry and Oxytocin on Frontotemporal Dementia", 
        "completion_date": {
            "#text": "March 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Frontotemporal Dementia", 
        "condition_browse": {
            "mesh_term": [
                "Dementia", 
                "Frontotemporal Dementia", 
                "Aphasia, Primary Progressive", 
                "Pick Disease of the Brain"
            ]
        }, 
        "detailed_description": {
            "textblock": "Frontotemporal dementia (FTD) and Pick's disease cause changes in personality, behaviour,\n      and emotional responses.  The usual treatments for Frontotemporal dementia focus on reducing\n      agitation and aggressive behaviours.  However, these drugs do not help all patients who\n      experience blunting of emotion and loss of empathy. This study will evaluate the effects on\n      emotions and neural activity of a one time dose of intranasal oxytocin vs. placebo in\n      patients with FTD and healthy controls."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Patients:\n\n          -  Ages 30-85\n\n          -  meet consensus criteria for probable behavioural variant FTD (bvFTD)\n\n        Controls:\n\n          -  Age and sex matched with patients\n\n          -  Mini-Mental State Exam (MMSE) scores >27\n\n        Exclusion Criteria:\n\n        Patients:\n\n          -  history of stroke\n\n          -  intracranial haemorrhage or other medical or neurological disorder apart from FTD\n             that could affect cognition\n\n          -  diagnosis of bipolar disorder or schizophrenia not better accounted for by the\n             diagnosis of FTD\n\n          -  cognitive impairment that precludes comprehension of task instructions\n\n          -  contraindication to MRI scanning\n\n          -  severe language or memory deficits that preclude participation in the study visits\n             and measures\n\n          -  females who are pregnant or breastfeeding (a pregnancy test will be done on females\n             who have not completed menopause).\n\n          -  uncontrolled hypertension\n\n          -  bradycardia (rate <48 bpm) or tachycardia (rate > 100 bpm)\n\n          -  current use of prostaglandins\n\n        Controls:\n\n          -  history of stroke\n\n          -  intracranial haemorrhage or other medical or neurological disorder\n\n          -  diagnosis of bipolar disorder or schizophrenia\n\n          -  cognitive impairment that precludes comprehension of task instructions\n\n          -  contraindication to MRI scanning\n\n          -  severe language or memory deficits that preclude participation in the study visits\n             and measures\n\n          -  females who are pregnant or breastfeeding (a pregnancy test will be done on females\n             who have not completed menopause).\n\n          -  uncontrolled hypertension\n\n          -  bradycardia (rate <48 bpm) or tachycardia (rate > 100 bpm)\n\n          -  current use of prostaglandins"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "85 Years", 
            "minimum_age": "30 Years"
        }, 
        "enrollment": {
            "#text": "72", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 3, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01937013", 
            "org_study_id": "R-13-270", 
            "secondary_id": [
                "166786", 
                "103555", 
                "FTDOXY13EF"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Intranasal Oxytocin", 
                "description": "Oxytocin can be given intravenously (with a needle) or intranasally (a spray into the nose).  The intravenous form of drug is approved by Health Canada for use in pregnancy.  The intranasal formulation is not currently approved for use by Health Canada, but is used in Europe to induce labour in pregnant women or aid lactation (breastfeeding). Participants will be randomized to receive 72 IU intranasal oxytocin on either study visit 2 or 3.", 
                "intervention_name": "Intranasal oxytocin", 
                "intervention_type": "Drug", 
                "other_name": "Syntocinon"
            }, 
            {
                "arm_group_label": "Saline Nasal Mist", 
                "description": "Participants will be randomized to receive placebo on either study visit 2 or 3.", 
                "intervention_name": "Saline Nasal Mist", 
                "intervention_type": "Drug", 
                "other_name": "Placebo"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Oxytocin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Frontotemporal Dementia", 
            "emotion", 
            "oxytocin", 
            "fMRI"
        ], 
        "lastchanged_date": "October 24, 2013", 
        "location": {
            "contact": {
                "last_name": "Kristy Coleman, BA", 
                "phone": "519-685-4242", 
                "phone_ext": "42398"
            }, 
            "facility": {
                "address": {
                    "city": "London", 
                    "country": "Canada", 
                    "state": "Ontario", 
                    "zip": "N6C 5J1"
                }, 
                "name": "Parkwood Hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "2", 
        "official_title": "Impact of Emotional Mimicry and Oxytocin on Frontotemporal Dementia", 
        "overall_contact": {
            "last_name": "Kristy KL Coleman, BA", 
            "phone": "519-685-4242", 
            "phone_ext": "42398"
        }, 
        "overall_official": [
            {
                "affiliation": "LawsonHRI, London Health Sciences Centre, Western University, Schulich School of Medicine", 
                "last_name": "Elizabeth A Finger, M.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Western University", 
                "last_name": "Derek Mitchell, PhD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Canada: Health Canada", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Measures of BOLD (Blood Oxygen-Level Dependent) signal change during oxytocin compared to placebo during functional MRI scans", 
            "measure": "Functional magnetic resonance imaging (fMRI) BOLD signal", 
            "safety_issue": "No", 
            "time_frame": "2 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01937013"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Lawson Health Research Institute", 
            "investigator_full_name": "Elizabeth Finger", 
            "investigator_title": "Principle Investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Performance on standardized tasks of emotion processing and cognition", 
            "measure": "Cognitive and Emotional Task performance", 
            "safety_issue": "No", 
            "time_frame": "2 weeks"
        }, 
        "source": "Lawson Health Research Institute", 
        "sponsors": {
            "collaborator": {
                "agency": "Canadian Institutes of Health Research  (CIHR)", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Lawson Health Research Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}